Advancements in Breast Cancer Screening and Treatment in Switzerland

Breast cancer remains a significant health concern for women in Switzerland, with approximately 6,600 new cases diagnosed annually, representing 30% of all female cancers. However, ongoing research and evolving treatment protocols are offering new hope for earlier detection and more effective care.

The Importance of Regular Screening

Early detection is crucial for improving breast cancer outcomes. While self-examination plays a role in awareness, medical professionals emphasize the reliability of regular mammograms. According to Dr. Didier Jallut, a medical oncologist and medical director of the breast network in Lausanne, “Performing mammograms regularly remains the most reliable way to detect breast cancer, to detect lesions that are not yet palpable, to operate on smaller cancers and to avoid remarkably heavy treatments.”

Challenges to Access and Coverage

Despite the proven benefits of mammography, access to screening isn’t uniform across Switzerland. Some cantons do not currently cover the cost of mammograms, raising concerns about equitable access to preventative care. Planned changes to the Tardoc rate in 2026 may threaten existing coverage in French-speaking Switzerland.

De-escalation of Treatments and Genomic Testing

Significant scientific advancements are enabling a more personalized approach to breast cancer treatment. Dr. Jallut highlights a trend towards “de-escalation of treatments,” where treatment protocols are tailored based on a comprehensive understanding of the tumor and individual patient factors. Genomic tests are increasingly used to assess the probability of benefit from chemotherapy, helping clinicians make more informed decisions.

The Role of Artificial Intelligence

Artificial intelligence (AI) is poised to revolutionize breast cancer diagnosis, and management. AI is already being utilized in the analysis of mammograms, working in conjunction with radiologists to improve diagnostic accuracy. Switzerland, with leading research institutions like EPFL, ISREC – Swiss Institute for Experimental Cancer Research – and the CHUV of Lausanne, is at the forefront of cancer research.

Future Directions: Liquid Biopsies and Early Detection

Researchers are actively exploring new methods for early disease detection, including the development of blood tests – often referred to as liquid biopsies – that could identify biomarkers indicative of breast cancer. “We are probably close to developing a blood test to facilitate detect the disease early,” notes Dr. Jallut, suggesting a potentially transformative shift in screening practices.